CELGENE STOCK ANALYSIS: Fighting Cancer
Celgene is the third largest biotech company in the world after Amgen and Gilead Sciences
Celgene is focused on oncology, that is, the treatment of cancers.
42% of revenue of Celgene comes from Revlimid which is used by patients with multiple myeloma.
Bristol-Myers Squib (BMS) is going to acquire Celgene in the coming months and there is the opportunity to make an arbitrage trade.